InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,870.62
(
-1.32%
)
US TECH 100
19,865.60
(
-2.37%
)
Dow Jones
43,444.99
(
-0.70%
)
Brent Oil
70.98
(
-1.71%
)
Bitcoin
91,335.46
(
4.55%
)
Post# of 253620
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120728
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rfj1862 post# 58802

Sunday, 02/10/2008 2:13:22 AM

Sunday, February 10, 2008 2:13:22 AM

Post# of 253620
Re: Pre-dosing with drug to screen patients for trials

Would you prefer the word strain rather than mutation? In any case, the maraviroc trial does not meet the criterion in pi’s post because patient eligibility for the trial was based on an assay rather than on clinical response to a drug during a run-in period.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up